tbuckley/cabot-search huggingface dataset:
Long-term cardiac safety and outcomes of dose-dense (dd) doxorubicin and cyclophosphamide (AC) followed by paclitaxel (T) and trastuzumab (H) with and without lapatinib (L) in patients (pts) with early breast cancer (BC).
Authors: C. T. Dang, P. G. Morris, S. Patil, C. Chen, A. Abbruzzi, R. Lehman, R. Steingart, L. Norton, C. Hudis
Journal: Journal of Clinical Oncology (2011)

579 Background: The addition of H to chemotherapy has improved outcomes in HER2-positive early BC. This approach is associated with (w/) an increased risk (<4%) of congestive heart failure (CHF). Dose-dense (every 2 weeks) anthracycline-taxane therapy (Rx) improves survival compared to the every 3 week schedule and can be combined w/ anti-HER2 Rx w/ no increased risk of cardiotoxicity. We report the long-term incidence of NYHA Class III/IV CHF in 2 phase II studies. Methods: We conducted a retrospective review of pts w/ HER2 + BC treated at MSKCC on two trials: In trial A - pts received dd AC (60/600 mg/m2) × 4 → T (175mg/m2) × 4 (w/ pegfilgrastim) w/ H × 1 year. Trial B differed w/ use of weekly T (80mg/m2) × 12 and addition of L (1000mg orally daily) × 1 year. Left ventricular ejection fraction (LVEF) was assessed by a multi-gated acquisition scan serially throughout Rx. Results: Trial A enrolled 70 pts w/ a median age of 49 yrs (range, 27-72) and median baseline LVEF of 68% (range 55-81%); 41/68 (69%) had node + BC; 2 had neoadjuvant Rx. Trial B enrolled 66 pts w/ a median age of 48 yrs (range 28-73) and median baseline LVEF of 68% (range 52-81%); 45/53 (83%) had node + BC; 13 had neoadjuvant Rx. Of these, 11 (16%) and 10 (15%) pts had pre-existing hypertension; 23 (33%) and 27 (41%) pts were smokers; 23 (33%) and 28 (42%) pts received left-sided radiation, in Trials A and B, respectively. Now at a median follow-up of 62 months and 36 months, only one (1.4%) and 2 (3%) pts developed CHF in Trial A and Trial B, respectively. No additional CHF events have occurred since the initial reports (median follow-up 2 yrs each). Overall, the crude disease-free survival rates are 93% (65/70) and 94% (62/66), and the crude overall survival rates are 97% (68/70) and 97% (64/66) in Trials A and B, respectively. Conclusions: Longer follow-up of these 2 studies demonstrate that dd AC → TH with or without L is not associated w/ an additional risk of CHF. This is consistent w/ the long-term cardiac toxicity reported by randomized phase III studies of H w/ conventionally scheduled anthracycline-based regimens (with or without taxanes). Survival outcomes are encouraging.
Glorified Hole
Authors: RICHARD L. MYEROWITZ
Journal: Annals of Internal Medicine (1977)

Comments and Correction1 February 1977Glorified HoleRICHARD L. MYEROWITZ, M.D.RICHARD L. MYEROWITZ, M.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-86-2-241_1 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptTo the editor: As a pathologist interested in clinical internal medicine, especially infectious diseases, I subscribe to several clinical journals such as ANNALS OF INTERNAL MEDICINE because they often contain reports with important clinico-pathologic correlations. I must protest, however, when I see published in them photomicrographs of poor quality that detract from the teaching value of these reports.The recent paper by Alpert and co-workers (1) on four patients with infective endocarditis and Osler's nodes from whom pathogenic organisms were seen and cultured makes the interesting point that these lesions may be embolic rather than "allergic." Part of the authors'...Reference1. ALPERTKROUSDALEN JHJ: Pathogenesis of Osler's nodes. Ann Intern Med 85:471-473, 1976 LinkGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: Presbyterian-University Hospital University of Pittsburgh School of Medicine Pittsburgh, PA 15213 PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 1 February 1977Volume 86, Issue 2Page: 241-241KeywordsEndocarditisInfectious diseasesLesionsPathogensPathologists Issue Published: 1 February 1977 PDF DownloadLoading ...
Fibromyalgia Syndrome
Authors: Don L. Goldenberg
Journal: JAMA (1987)

The clinical manifestations, laboratory findings, and treatment results of 118 patients with fibromyalgia followed up by one investigator were compared with those of other recent reports. The history of this syndrome and recent efforts to establish diagnostic criteria and to understand underlying pathophysiologic mechanisms were studied. A practical, noninvasive office-based evaluation and conservative treatment approach were developed, determined by an understanding of the natural history of this common but controversial disorder. (<i>JAMA</i>1987;257:2782-2787)
Productivity of women physicians
Authors: M. Heins
Journal: JAMA (1976)

Personal interview data obtained from 87 randomly selected women physicians in metropolitan Detroit indicates that productivity of women physicians has increased over that shown in previous studies. Eighty-four percent were engaged in medical work at the time of survey, 90% full-time. Only 7% were not working for reasons related to being a woman. Fifty-nine percent had worked continuously full-time since medical school graduation. Nearly half do not plan to retire from medical work. Fifty-eight percent are in private practice and 51% in primary care specialties; 54% are board certified. Direct patient care was listed as their main task by 86% of the women. Sixtyseven percent are married (43% to physicians). Although the 87 women physicians have responsibilities for households containing a total of nearly 300 people, almost one third of whom are children under 18 years old, their productivity is high. (<i>JAMA</i>236:1961-1964, 1976)
A phase I trial of 1,3-bis(2-chloroethyl)-1-nitrosourea plus temozolomide: A North American Brain Tumor Consortium study
Authors: S. Clifford Schold, John G. Kuhn, Susan M. Chang, Michael E. Bosik, H. Ian Robins, Manesh P. Mehta, Alexander M. Spence, Dorcas Fulton, Karen L. Fink, Michael D. Prados
Journal: Neuro-Oncology (2000)

The North American Brain Tumor Consortium conducted a phase I trial of the combination 1,3-bis(2chloroethyl)-1-nitrosourea (BCNU) and temozolomide.Eligibility included a patient with a cancer type that was considered refractory to standard therapy.Prior nitrosourea treatments were not permitted.There were parallel dose escalations in two treatment schedules.Forty-five patients were enrolled during an 18-month period.The maximum tolerated doses (MTDs) when temozolomide followed BCNU (Arm A) were temozolomide at 550 mg/m 2 /p.o. and BCNU at 150 mg/m 2 /i.v.), whereas the MTD when temozolomide preceded BCNU (Arm B) was temozolomide at 400 mg/m 2 /p.o. and BCNU at 100 mg/m 2 /i.v.Toxicity was predominantly hematologic, although there were three instances of pulmonary toxicity, which in one case could have represented potentiation of nitrosourea-induced pulmonary brosis.The half-life of temozolomide was 1.86 (±0.31) h.There was a moderate relationship between dose and peak concentration and a strong relationship between dose and plasma concentration time curve.Pharmacokinetic parameters of temozolomide were unaffected by the treatment schedule, so the difference in MTD between the schedules is likely due to a biologic rather than a pharmacokinetic sequence interaction.There were 9 partial responses among 43 patients evaluable for response, including 5 of 25 with a histologic diagnosis of glioblastoma.The recommended dose and schedule for phase II trials of this regimen are BCNU 150 mg/m 2 /i.v.followed in 2 h by temozolomide 550 mg/m 2 /p.o.repeated every 6 weeks.We are also recommending screening and periodic pulmonary function testing during treatment to assess the possible potentiation of nitrosourea-induced pulmonary fibrosis.
Increased Prevalence of Seizure Disorders Among Prisoners
Authors: Lambert N. King, Quentin D. Young
Journal: JAMA (1978)

In an effort to determine the prevalence of seizure disorders among persons confined to jails and prison, the prescription rates for anticonvulsant medications in ten Illinois correctional institutions were surveyed. The institutions housed 12,030 persons at the time of the survey. Analysis of the results of the survey suggests a point prevalence of seizure disorders of 1.9% among the Illinois prison and jail population. This estimated prevalence of seizure disorders is approximately three times higher than among middleclass nonprisoner populations on which previous epidemiologic studies of epilepsy have been based. Special programs and resources for the detection, treatment, and prevention of seizure disorders among prisoners appear necessary. Provisions to ensure continuity of care after release from incarceration are also needed. (<i>JAMA</i>239:2674-2675, 1978)
Autoantibodies to the functionally active RING-domain of Ro52/SSA associate with clinical activity in a subset of patients with lupus
Authors: Marika Kvarnström, Vijole Dzikaite, Lars Ottosson, Iva Gunnarsson, Elisabet Svenungsson, Marie Wahren-Herlenius
Journal: Annals of the Rheumatic Diseases (2012)

<h3>Introduction</h3> Systemic lupus erythematosus (SLE) is a disease with immunological dysregulation, and affects patients commonly carrying autoantibodies in combination with involvement of at least two organ systems affected by inflammation. The different autoantibody specificities correlate with specific clinical manifestations and thus prognosis. Ro/sjögren9s syndrome A (SSA) and LA/sjögren9s syndrome B (SSB) autoantibodies are common in lupus, and have been described to correlate with a milder phenotype. In the present study the authors wanted to investigate correlations of levels and clinical implications of Ro/SSA and La/SSB autoantibodies including autoantibodies directed towards the functional RING and B-Box domains of the Ro52 protein. <h3>Methods</h3> Blood samples from SLE patients (n=232) were analysed for immunological parameters including autoantibodies. All patients were concurrently examined by a rheumatologist and a nurse and information on clinical manifestations and disease activity indices collected. <h3>Results</h3> Ro52 autoantibody levels associated with more variables than the other analysed antibodies. Significance was found for disease activity measured with the SLAM score (p=0.031), several variables involved in secondary Sjögren9s syndrome (sSS) and items for a diagnosis of sSS: (sSS p=0.0041; whole unstimulated salivary flow less than 1.5 ml/15 min p=0.027; salivary production measurement p=0.0076, a positive Schirmer9s test p=0.046; tear production p=0.019), sedimentation rate (p=0.0003), levels of immunoglobulins (p=0.0003), and an inverse correlation with levels of lymphocytes (p=0.003) and leucocytes (p=0.011). Antibodies to the RING domain of Ro52, which is the functionally active domain with E3 ligase activity, were highly significant for disease activity (p&lt;0.0001). <h3>Conclusion</h3> Autoantibodies against Ro52 and the functional RING domain are important in lupus patients and associate more than Ro60 and La antibodies with clinical and laboratory features of the disease. The impact on the SLAM disease activity score was especially noted.
Expression of Granulocyte-Macrophage Colony-Stimulating Factor Receptors in Human Prostate Cancer
Authors: Coralia I. Rivas, Juan Carlos Vera, Fernando Delgado-López, Mark L. Heaney, Victor H. Guaiquil, Rong H. Zhang, Howard I. Scher, Ilona I. Concha, Francisco Nualart, Carlos Cordon-Cardo, David W. Golde
Journal: Blood (1998)
The Gamma Globulins
Authors: Ezio Merler, Fred S. Rosen
Journal: New England Journal of Medicine (1966)

Gamma-G GlobulinγG globulin comprises at least 80 per cent of the serum antibodies of the adult. Antibodies to gram-positive pyogenic bacteria, antiviral antibodies and antitoxins in human serum from adults are found almost exclusively among the γG globulins.γG globulin contains about 2.5 per cent by weight of carbohydrate.82 The sugar is associated with the γ chain, but its precise localization on the γ chain is not known. Of this sugar, there is 1.2 per cent galactose and mannose, 1.4 per cent hexosamine, 0.3 per cent fucose and 0.2 per cent sialic acid. At least in the rabbit all . . .
Academic sanction. Targeting South African science
Authors: R. Crawshaw
Journal: JAMA (1989)

Academic sanction, the intentional denial of scholarly exchange for political reasons, presents grave practical and moral problems to the open pursuit of medical science. The focus of this article targets South African science. However, examples of academic sanction in Western Europe, the United States, the Soviet Union, China, Japan, and other areas are given to support the existence of discriminatory restrictions against scientists. Examples and reasons also are offered for and against academic sanction, with the recommendation that academic sanction be pursued only with judgment informed by factual knowledge as well as moral, ethical, and compassionate values. (<i>JAMA</i>. 1989;262:1499-1503)
Cardiac catheterization in a community hospital
Authors: P. B. Jennings
Journal: JAMA (1967)

The role of the community hospital in the performance of specialized diagnostic procedures has been under scrutiny recently by hospital administrators, the federal government, and practicing physicians. With this in mind, the results of eight years of cardiac catheterization in a community hospital have been surveyed. Results support the concept that this is a low-risk procedure, and that a community hospital offers an excellent place for screening potential surgical candidates. Discussion shows the value of such a laboratory to patient, physician, and community.
Increased Iron Export By Ferroportin Induces Restriction of HIV-1 Infection in Sickle Cell Disease By SAMHD1
Authors: Namita Kumari, Tatiana Ammosova, Sharmeen Diaz, Xionghao Lin, Xiaomei Niu, Andrey Ivanov, Subhash Dhawan, Patricia A. Oneal, Sergei Nekhai
Journal: Blood (2016)
American Medical Association Auxiliary, Inc. 1985 Annual Convention June 16 through 19, 1985 Drake Hotel, Chicago
Journal: JAMA (1985)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Use of BCG Vaccines in the Control of Tuberculosis: A Joint Statement by the ACIP and the Advisory ACIP Committee for Elimination of Tuberculosis
Journal: JAMA (1988)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Ecstasy, the Serotonin Syndrome, and Neuroleptic Malignant Syndrome—A Possible Link?-Reply
Authors: Richard Friedman
Journal: JAMA (1993)

<h3>In Reply.</h3> —The report of toxic reactions to the designer drug, ecstasy, in Ms Randall's<sup>1</sup>report bears a striking resemblance to the serotonin syndrome reported in psychiatric patients.<sup>2</sup>Like some patients with the serotonin syndrome, individuals who used ecstasy were noted to have hyperthermia, tachycardia, disseminated intravascular coagulation, rhabdomyolysis, and acute renal failure. The serotonin syndrome is characterized by some or all of the following symptoms: hyperthermia, tachycardia, autonomic instability, agitation, diaphoresis, myoclonus, shivering, tremor, and mental status change (ie, confusion or delirium).<sup>2</sup>Clinical reports describe symptoms ranging from very mild to life-threatening. We previously reported a near-fatal case in which the patient developed hyperthermia, disseminated intravascular coagulation, rhabdomyolysis, and acute renal failure.<sup>3</sup> The serotonin syndrome has been reported in patients who are treated with a combination of agents that markedly enhance brain serotonin activity. The most common serotonergic drug interactions associated with this syndrome include
DIELDRIN INTOXICATION
Authors: Mitchell R. Zavon
Journal: JAMA (1960)

<h3>To the Editor:—</h3> InThe Journal, April 30, page 2077, is a report from the Committee on Toxicology which is in many ways misleading in its implications and may have results which were not intended by the committee. The report in question, "Occupational Dieldrin Poisoning," purports to review chronic occupational intoxication. It is not possible to determine from the report what is meant by the term "chronic." Does this refer to long-continued illness resulting from a single exposure, only to those from multiple exposures, or only to long-continued (chronic) exposure without reference to the duration of illness? To me, chronic occupational illness means illness of occupational origin persisting for a long time. There is some question as to whether dieldrin is capable of causing a chronic clinical illness, although electroencephalographic changes may persist for some time after the acute syndrome. The one new case reported in the review is an
Medical and Nonmedical Uses of Anabolic-Androgenic Steroids
Journal: JAMA (1990)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Management of the Sick Infant.
Journal: JAMA (1933)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Cancer Therapy
Authors: W. C. Hueper
Journal: JAMA (1962)

<h3>To the Editor:—</h3> The editorial entitled "Evaluation of Cancer Case Management" (<i>JAMA</i><b>178</b>:1103 [Dec. 16] 1961) contains the following categorical statement: "Until medical research unlocks the secrets of cancer etiology, which, hopefully, will lead to the development of preventive and prophylactic measures, we must continue the search for more effective diagnostic and therapeutic techniques." While I am afraid that the search for better diagnostic and therapeutic measures will have to continue even when the causal agents of cancers have been discovered, it is a misstatement of fact that the development of preventive and prophylactic measures must await the unlocking of the secrets of cancer etiology. Industry throughout the world has applied more or less successfully, for years, to some degree, and in some haphazard way, preventive and prophylactic measures for the protection of its workers against occupational cancer hazards. The State of Pennsylvania recently employed, in fact, the most
Managing hyperacute ischaemic stroke with interventional neuroradiology
Journal: BMJ (2012)

The third and fourth sentences of the sixth paragraph should read: "Recanalisation rates of 65-90% have been achieved using endovascular techniques, but favourable outcome (a modified Rankin score ≤2 at three months) is achieved in only 25-60% of cases. 6This is probably because some patients are treated too late for recanalisation to be effective [not "for recanalisation to occur"].